TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01873157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11.
Study: NCT00618124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248; Capecitabine
Description: Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
Study: NCT03102008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Emotional Disorders in Adolescents (UP-A)
Description: The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
Study: NCT01422707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10 mg/m2/per day PO at bedtime (X4 weeks)
Study: NCT03341494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Gefitinib 250mg Thalidomide 200 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Gefitinib 250mg Thalidomide 200 MG
Study: NCT03433300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ottobock Kenevo/C-Leg
Description: Microprocessor-controlled prosthetic knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ottobock 3R60/3R62
Description: Nonmicroprocessor-controlled knee
Study: NCT02195596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise+strength
Description: The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity aerobic exercise+strength
Description: Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~--------------------------------------------------------------------------------
Study: NCT02412878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Commercially available dexamethasone was obtained by the investigational site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Commercially available dexamethasone was obtained by the investigational site.
Study: NCT03038776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine
Study: NCT01530893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin - food
Description: acute single optimal dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin - placebo
Description: acute single dose (anthocyanin free)
Study: NCT03616795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3154207
Description: Administered orally
Study: NCT00556647

Intervention type: PROCEDURE
Intervention: fast track diagnosis
Description: fast-track diagnosis, PET-CT, bronchoscopy

Intervention type: PROCEDURE
Intervention: conventional diagnosis
Description: out-patient diagnosis
Study: NCT02413814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Reduction Treatment
Description: Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
Study: NCT03038776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza hemagglutinin
Description: Avian H7N9 influenza vaccine
Study: NCT02780960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV self-testing
Description: Patients will perform HPV testing themselves at home.
Study: NCT03055494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
Study: NCT02102594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
Study: NCT02000882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT03073356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 3-OHB
Description: Increase in 3-OHB levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 3-OHB
Description: Increase in 3-OHB levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 3-OHB
Description: Increase in 3-OHB levels
Study: NCT01227616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: IV Iron Sucrose
Study: NCT04328103

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.

Intervention type: BEHAVIORAL
Intervention: Nonspecific Supportive Therapy (PBO)
Description: As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
Study: NCT00920647

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase IT (1 mg)
Description: The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase IT (10 mg)
Description: Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase IT (30 mg)
Description: Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
Study: NCT03128671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAVoR Intervention
Description: The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
Study: NCT00865852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 750 mg Extender Release tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE® XR 750 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study: NCT00723385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 or 2000 IU/day)
Description: Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo for 12 weeks with repeated D measurements
Study: NCT04687098

Intervention type: DRUG
Group type: OTHER
Intervention: Idarubicin
Description: 12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.

Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: 200mg/m2/day, intravenous at induction phase; days 1-7.~- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5.

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: * Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic matched or unrelated donor transplant.
Description: To be performed in patients in the intermediate or adverse risk groups.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous peripheral blood stem cell transplant
Description: To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measurable residual disease
Description: To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
Study: NCT03534583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
Study: NCT00730821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study: NCT02884492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-THK-5351
Description: 18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-THK-5351
Description: 18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
Study: NCT01124838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
Study: NCT05366049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using a medicine pacifier to give acetaminophen
Description: While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: using a medicine pacifier to give acetaminophen
Description: While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
Study: NCT02065570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03600038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental smoking cessation smartphone app
Description: The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care smoking cessation smartphone app
Description: The control intervention uses a standard of care smartphone smoking cessation app.
Study: NCT01013935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE+ Spanish computer counseling session
Description: The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE+ Spanish brief computer risk assessment session
Description: The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
Study: NCT05276323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney Derma Cream
Description: applied topically, twice a day, on all affected areas in the body for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone 1% cream
Description: applied topically, twice a day, on all affected areas in the body for two weeks.
Study: NCT00287469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis E vaccine, recombinant (Sar 56 kDa)
Description: 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBS buffer placebo containing alum
Study: NCT00065468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa
Description: Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779
Description: 25 mg of CCI-779 given Intra Venously once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa and CCI-779
Description: 15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
Study: NCT03309124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked potato with skin
Description: Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
Study: NCT03073356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 3-OHB
Description: Increase in 3-OHB levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of placebo
Description: NaCl

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of placebo
Description: NaCl

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of placebo
Description: NaCl

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of placebo
Description: NaCl
Study: NCT04609449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long biliopancreatic limb Roux-en-Y gastric bypass.
Description: Long biliopancreatic limb Roux-en-Y gastric bypass.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Roux-en-Y gastric bypass
Description: Standard Roux-en-Y gastric bypass
Study: NCT00003513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01402986

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Q2W
Description: Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg, Q2W
Description: Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Q2/4W
Description: Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg, Q2/4W
Description: Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Study: NCT02227719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTI
Description: CTI is the titanium mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane